In conclusion, we have demonstrated that, in a small cohort of patients without T2D, SGLT2 inhibition was not able to alter the hepatic TAG content or the processes that are crucial to its pathogenesis. Here, SLC5A2 is linked to type 2 diabetes mellitus.